Edgewise Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EWTX research report →
Companywww.edgewisetx.com
Edgewise Therapeutics, Inc. , a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.
- CEO
- Kevin Koch
- IPO
- 2021
- Employees
- 117
- HQ
- Boulder, CO, US
Price Chart
Valuation
- Market Cap
- $3.53B
- P/E
- -19.97
- P/S
- 0.00
- P/B
- 7.13
- EV/EBITDA
- -18.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -32.55%
- ROIC
- -40.15%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-167,795,000 · -25.40%
- EPS
- $-1.63 · -12.41%
- Op Income
- $-191,406,000
- FCF YoY
- -30.34%
Performance & Tape
- 52W High
- $39.96
- 52W Low
- $12.15
- 50D MA
- $32.20
- 200D MA
- $23.80
- Beta
- 0.25
- Avg Volume
- 1.04M
Get TickerSpark's AI analysis on EWTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 5, 26 | Donovan Joanne M. | other | 50,000 |
| May 5, 26 | Donovan Joanne M. | other | 50,000 |
| May 5, 26 | Donovan Joanne M. | sell | 50,000 |
| May 4, 26 | Donovan Joanne M. | sell | 5,230 |
| Apr 1, 26 | Fox Jonathan C | other | 339 |
| Apr 1, 26 | Donovan Joanne M. | other | 28,662 |
| Apr 1, 26 | Donovan Joanne M. | other | 28,662 |
| Apr 1, 26 | Donovan Joanne M. | sell | 28,662 |
| Mar 31, 26 | Donovan Joanne M. | other | 21,338 |
| Mar 31, 26 | Donovan Joanne M. | other | 21,338 |
Our EWTX Coverage
We haven't published any research on EWTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EWTX Report →